Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Acute Myeloid Leukemia (AML) based on specific internationally recognised diagnostic guidelines (WHO 2022 or ICC criteria)
- People aged between 55 and 75 years old
- People who are reasonably active and able to carry out daily activities — assessed using a standard scale where a score of 0 means fully active and 2 means able to care for oneself but unable to do physical work
- People whose liver is functioning well enough, based on blood test results showing liver-related values within acceptable ranges
- People whose kidneys are functioning well enough, based on blood test results within acceptable ranges
- People whose heart enzyme levels are within acceptable ranges on blood tests
- People whose heart is pumping blood effectively, confirmed by a heart ultrasound (echocardiogram) showing a normal result
- People who have given written agreement to participate (or whose legal representative has done so)
Who may not be able to join:
- People whose AML involves a specific genetic change called PML-RARA fusion — a subtype known as Acute Promyelocytic Leukemia
- People whose AML involves specific genetic changes called RUNX1-RUNX1T1 or CBFB-MYH11 fusions
- People whose AML involves a specific genetic change called BCR-ABL fusion
- People whose AML has come back after treatment or has not responded to previous chemotherapy (note: prior use of a drug called hydroxyurea is generally acceptable)
- People who have another type of cancer that currently requires treatment
- People with serious heart conditions, such as uncontrolled chest pain, a recent heart attack, severe irregular heartbeat, uncontrolled heart failure, or an abnormal heart pumping result
- People with severe active infections, such as untreated tuberculosis or a serious fungal lung infection called pulmonary aspergillosis
- People who the trial doctor considers unsuitable for other medical reasons (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Phone: 13132507161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.